stockrow
Saturday 7 November 2026
Export ELTX’s income statement to Excel — free account
Elicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
- EPS
- +34.9%
- Free cash flow
- +8.77%
- Total debt
- +2.12%
Quarter to June 2026, against a year earlier
1.52
0.12
+8.57%
Follow ELTX
Alert me
Elicio Therapeutics, Inc. (ELTX) P/E ratio
Elicio Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELTX Elicio Therapeutics, Inc. | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IBO Impact Biomedical Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)